Ind-Swift Laboratories declared their Q3 FY24 results on 12 Feb, 2024. The topline decreased by 8.05% & the profit decreased by 29.38% YoY.
As compared to the previous quarter, the revenue declined by 0.76% and the profit decreased by 38.66%.
The Selling, general & administrative expenses declined by 1.01% q-o-q & increased by 11.63% Y-o-Y.
The operating income was down by 27.37% q-o-q & decreased by 0.62% Y-o-Y.
The EPS is ₹3.29 for Q3 FY24 which decreased by 29.25% Y-o-Y.
Ind-Swift Laboratories has delivered -9.27% return in the last 1 week, 9.66% return in the last 6 months, and -4.59% YTD return.
Currently, Ind-Swift Laboratories has a market cap of ₹583.78 Cr and a 52wk high/low of ₹123.4 & ₹53.95 respectively.
Ind-Swift Laboratories Financials
Period | Q3 FY24 | Q2 FY24 | Q-o-Q Growth | Q3 FY23 | Y-o-Y Growth |
---|---|---|---|---|---|
Total Revenue | 287.51 | 289.71 | -0.76% | 312.69 | -8.05% |
Selling/ General/ Admin Expenses Total | 37.08 | 37.46 | -1.01% | 33.22 | +11.63% |
Depreciation/ Amortization | 13.56 | 13.19 | +2.79% | 15.39 | -11.92% |
Total Operating Expense | 249.38 | 237.2 | +5.13% | 274.31 | -9.09% |
Operating Income | 38.13 | 52.51 | -27.37% | 38.37 | -0.62% |
Net Income Before Taxes | 24.19 | 38.77 | -37.59% | 24.35 | -0.63% |
Net Income | 19.42 | 31.66 | -38.66% | 27.5 | -29.38% |
Diluted Normalized EPS | 3.29 | 5.36 | -38.62% | 4.65 | -29.25% |
Catch all the Business News , Corporate news , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.